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Summary. — Few cross section measurements have been performed at the n TOF
facility at CERN with the aim of supplying nuclear data for some neutron-induced
reactions of importance in Neutron Capture Therapy. In this paper, a brief intro-
duction to the topic will be presented as well as a discussion on the status of the
nuclear data available prior to the executions of the experiments.
1. – Introduction
1.1. Neutron Capture Therapy . – NCT is a selective binary experimental radiotherapy
based on the neutron irradiation of a tumour previously loaded with a suitable stable
isotope. Incoming neutrons induce a high Q-value nuclear reaction in the isotope, causing
the emission of high LET (Linear Energy Transfer) radiation with an energy deposition
range of 5 to 9 μm, which is comparable to the cancerous cell size. As a result of the
energy deposition, the cancer cell is damaged. 10B is the isotope that is normally used
in this radiotherapy, and 10B(n, α)7Li the reaction induced by neutrons reaching the
tumour. In the past, patients were taken to nuclear reactors to receive the necessary
neutron irradiation, this posed logistical problems that significantly limited the potential
of this therapy. Nowadays, the development of accelerator-based neutron sources for
NCT opens the possibility to implement this therapy in hospitals [1], taking advantage
of more versatile and safe neutron beams. This paradigm shift inaugurates a new era
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for NCT, therefore, many aspects of this therapy must be studied in detail in order
to improve its therapeutic outcome. The use of 33S as a cooperative target to 10B was
proposed in 2008 [2,3]. The most probable neutron-induced reaction channel of this stable
isotope is 33S(n, α), presenting important resonances above 10 keV. These resonances can
be used to increase the delivered dose to the tumour loaded with 33S, especially when
using accelerator based neutron sources, which provide neutrons in the epithermal range
of energy. Regarding the dosimetry specifications, the International Commission on
Radiation Units and Measurements (ICRU) recommends that the delivered dose should
have less than 5% deviation from the prescribed dose [4]. Therefore, a good knowledge
of the nuclear reactions involved is required; what will lead to a better control of the
released dose through more accurate estimation of the therapy safety margins. Moreover,
chlorine is present in human body tissue, especially in the brain where it represents a
fraction of 0.3% in mass. Accordingly, neutron-induced reactions on chlorine may play an
important role. Using Monte Carlo simulations, it was concluded that 35Cl(n, p)35S and
35Cl(n, γ)36Cl reactions should be included accurately in NCT dosimetry studies [5, 6],
due to their cross section resonances in the epithermal region, the high LET of the
released proton in the first reaction and the high Q-value of the 35Cl(n, γ)36Cl reaction
(approximately 8.58 MeV).
In order to improve the dosimetry studies of this therapy and to explore the po-
tential of 33S as a cooperative target to 10B, several cross section measurements were
performed at the neutron time of flight facility (n TOF) at the European Organization
for Nuclear Research (CERN), since the status of the available nuclear data was not
optimal according to the recommendations of the ICRU.
1.2. Neutron Time Of Flight facility at CERN . – n TOF is a spallation neutron source
based on a 20 GeV/c proton beam impinging on a lead target [7,8]. n TOF is a unique
facility in the world due to the state of the art of its detectors, the data acquisition system
and the characteristics of its neutron beam, i.e., high instantaneous flux in a wide energy
range —from few meV to several GeV—, high energy resolution which allows resolving
resonances and low repetition rate of the primary pulsed proton beam. The facility is in
operation since 2001 and features two experimental areas: n TOF-EAR1 [9], located at
185 m from the spallation target along the horizontal direction of the incoming proton
beam, and n TOF-EAR2 [10], along the vertical direction at 20 m from the target, which
was built in 2014. n TOF is mainly dedicated to measure neutron-induced cross sections
for nuclear technology, astrophysics, basic nuclear physics and medical physics.
2. – Nuclear data status before the n TOF measurements
The 33S(n, α)30Si cross section data available showed important deficiencies, as dis-
cussed in [11], with no experimental data between thermal (25 meV) and 10 keV, and
major discrepancies at the thermal point. There was only one (n, α) experiment resolving
resonances [12]. An important discrepancy was found between such experiment and the
description of the most important resonance by means of the unique transmission mea-
surement [13]. With respect to the evaluated nuclear data files, only EAF-2010 includes
the resonance, but with a lower average cross section than the one reported in ref. [12].
For the 35Cl(n, p)35S reaction, the cross section data showed significant discrepancies
among existing data sets in both the resonance region and the thermal point, leading
to some complications in the nuclear data evaluation [14], as it is widely discussed in
ref. [5].
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The reaction 14N(n, p)14C is of great importance in NCT, with the biggest contribu-
tion to the energy deposition in brain tissue for neutrons with energies below 50 eV, in
absence of 10B [15]. However, as explained in ref. [5], some discrepancies with potentially
crucial consequences for NCT were identified in the available nuclear data.
The quality of the data available for the 35Cl(n, γ)36Cl reaction in the resonance re-
gion limited the accuracy of the cross section determination. This has led to discrepancies
in the cross section evaluations across the major libraries, evidenced in ref. [6]. The only
measurement in the resonance region was performed using natural Chlorine [16], and the
measurements of the cross section at the thermal point showed too large discrepancies
for NCT dosimetry calculations, as shown in ref. [6].
3. – Experiments
3.1. 33S(n, α)30Si. – The measurement of the cross section was performed at n TOF-
EAR1 for the resonance region [17] and at n TOF-EAR2 for neutron energies down to
0.01 eV [11]. In both cases, a setup of in-beam gaseous micromegas detectors [18] was
used. Two important results were found: the 1/v behaviour below 10 keV, and a much
higher area of the resonance at 13.5 keV than the one obtained in ref. [12], in agreement
with the transmission measurement [13]. Fig. 1 (left) shows the combination of the
data obtained in both experiments for the cross section measurement. The potential of
33S as a cooperative target for NCT was evaluated in ref. [19] using the new n TOF
cross section data, where it can be seen that adding sulfur could be very appropriate for
treating superficial tumors.
3.2. 14N(n, p)14C and 35Cl(n, p)35S. – A combination of in-beam micromegas detec-
tors and off-beam DSSSD detectors was used in our experimental setup [5] at n TOF-
EAR2. With the micromegas detectors collecting most of the statistics, the DSSSDs
were used to study any possible anisotropy of the emitted protons in the most important
resonances. The analysis of the data is an ongoing work; preliminary results of the yield
are shown in fig. 1 (right), where cross sections are shown up to 100 keV. Our goal is to
extend the neutron energy range up to 500 keV or even 1 MeV. In this experiment, the
micromegas setup has proved to be suitable for measuring (n, cp) reaction cross sections
for low energy charged particles (approximately 400 keV) in the neutron energy range
which extends from thermal up to 100 keV.
Fig. 1. – Differential cross sections obtained at n TOF using micromegas detectors: 33S(n, α)30Si
reaction (left); preliminary results for the 14N(n, p)14C and 35Cl(n, p)35S reactions (right).
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3.3. 35Cl(n, γ)36Cl. – In order to measure the 35Cl(n, γ)36Cl cross section, four C6D6
liquid scintillators [20], widely used for capture measurements at n TOF, were employed
at n TOF-EAR1. The data analysis of this experiment is at an early stage, but some of
the 35Cl(n, γ)36Cl resonances have been already identified.
4. – Conclusions
NCT faces a new era due to the development of accelerator-based NCT facilities.
There is room to improve its therapeutic outcome from many different perspectives,
such as the investigation of alternative and cooperative isotopes to 10B, or the improve-
ment of dosimetric calculations, which requires accurate nuclear data that is not always
available. For this reason, in recent years, important efforts have been made by the
n TOF Collaboration seeking to solve this lack of data by conducting experiments aimed
to obtain the cross section of those reactions of interest for this therapy. Four reactions
have been studied so far and the data analysis of some of them is a work in progress.
The resulting nuclear data will, ideally, allow the NCT community to plan treatments
capable of increasing the dose delivered to tumours, improving the chances of patient
survival.
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